MYLK4

Across TCGA pan-cancer cohorts, MYLK4 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MYLK4 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher MYLK4 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MYLK4 expression acts as an unfavorable survival marker.

BRCA, SKCM, and ESCA are the cancer types where MYLK4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	DFS	Median	All	0.250	0.903	<.001	36	view →
SKCM	OS	Median	III,IV	0.179	0.721	<.001	16	view →
ESCA	OS	Median	II,III,IV	0.248	0.686	.019	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUSC	DFS	Median	II,III,IV	0.268	0.597	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MYLK4–BRCA (DFS)

Open the BRCA breakdown →